Jump to ContentJump to Main Navigation
The Lock and Key of MedicineMonoclonal Antibodies and the Transformation of Healthcare$
Users without a subscription are not able to see the full content.

Lara V Marks

Print publication date: 2015

Print ISBN-13: 9780300167733

Published to Yale Scholarship Online: January 2016

DOI: 10.12987/yale/9780300167733.001.0001

Show Summary Details
Page of

PRINTED FROM YALE SCHOLARSHIP ONLINE (www.yale.universitypressscholarship.com). (c) Copyright Yale University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in YSO for personal use (for details see www.yale.universitypressscholarship.com/page/privacy-policy).date: 16 October 2018

A Hesitant Start

A Hesitant Start

Patents, Politics, and Process

Chapter:
(p.25) Chapter Two A Hesitant Start
Source:
The Lock and Key of Medicine
Author(s):

Lara V. Marks

Publisher:
Yale University Press
DOI:10.12987/yale/9780300167733.003.0002

This chapter discusses how the dissemination of monoclonal antibodies (Mabs) involved complex negotiations between actors in numerous scientific laboratories across the world, negotiations that also played out on the political stage. Central questions arose over who possessed rights to the technology, and whether those rights should be protected. Much of the debate about rights was shaped by whether scientists believed the technique was revolutionary or merely part of a long chain of scientific discoveries. In 1975, Mabs were not particularly new either theoretically or conceptually because similar antibodies had been produced before. The difference was essentially one of scale. While British immunologist César Milstein and other experts recognized the technology's potential early, the National Research and Development Corporation (NRDC) initially expressed doubts regarding the application of Mabs, and thus refused to patent the technique. The eventual collaboration between Sera-Lab and Milstein's laboratory provided the first commercial channel for the global dissemination of Mabs, and established an important foundation for future research in the field.

Keywords:   Mabs, monoclonal antibodies, César Milstein, dieresis>hler, National Research and Development Corporation, Sera-Lab

Yale Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us.